Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Drops By 12.0%

AlloVir, Inc. (NASDAQ:ALVR) was the target of a large decline in short interest in December. As of December 15th, there was short interest totalling 1,690,000 shares, a decline of 12.0% from the November 30th total of 1,920,000 shares. Based on an average daily trading volume, of 354,200 shares, the short-interest ratio is presently 4.8 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AlloVir stock. Cubist Systematic Strategies LLC increased its holdings in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,816 shares of the company’s stock after acquiring an additional 30,072 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent filing with the Securities & Exchange Commission. 66.05% of the stock is owned by hedge funds and other institutional investors.

AlloVir Price Performance

Shares of NASDAQ ALVR opened at $0.45 on Tuesday. The stock has a market capitalization of $51.76 million, a P/E ratio of -0.51 and a beta of 0.59. AlloVir has a one year low of $0.40 and a one year high of $1.05. The firm’s 50 day simple moving average is $0.62 and its two-hundred day simple moving average is $0.71.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.